Home

11

Feb

2013

NVCA Launches BIG:VC Study PDF Print E-mail

Emily Mendell

Written by Emily Mendell   
Share

On Friday, the NVCA, along with our partners at Dow Jones Venture Source, DeSantis Breindel and Rooney & Associates launched a first-time survey called the Brand Influence Guide for Venture Capital or BIG: VC.

The survey was borne from a proposal to NVCA from the NY based branding and PR firms DeSantis Breindel and Rooney & Associates to explore how brand perception is viewed in the venture capital industry.  Does a VC firm’s brand matter?  To founders?  To LPs?  To one another?

This topic is one with which the venture industry has been grappling in the last few years as more and more firms are focusing on building their unique brands to attract investors and strengthen deal flow.  But what really resonates with the audiences so important to our industry?  What brand attributes make a difference? And how does a firm best convey the strengths it chooses to put forth?

It was a series of questions we at NVCA wanted to answer.  We worked closely with some of the best marketing and communications professionals in the venture industry to design the survey and we expect the results to be extremely enlightening.

The survey – which comprises separate questions for VCs, CEOs and LPs - will run through the month of February.  If you are a venture professional, company founder or limited partner in a venture fund and want to take 5 minutes to give us your thoughts on brand perception within the VC industry, please email me at emendell@nvca.org and I will get you the link.  All survey respondents have the option to receive final results.

We hope to hear from you!

 

07

Feb

2013

Raising Money In Emerging Markets - Fairytale? PDF Print E-mail

Jeanne Metzger

Written by Jeanne Metzger   
Share

There has been a lot of discussion in recent months about the viability of raising venture capital funds from international capital sources. The challenge for many in the U.S. venture capital market is that with limited experience and knowledge of these emerging markets it's challenging to develop an effective strategy. To help in this regard, NVCA recently asked O'Meleveny & Myers LLP to create a white paper about the fundraising landscape in the emerging markets they have seen venture capitalists successfully raise money.

Today, NVCA released this paper to its membership and we encourage anyone interested in learning more about the fundraising landscape overseas to take a look. The piece discusses China, Japan, Singapore, South Korea, Peru, Chile, and Brazil. The authors highlight why each market is worth considering, who the key LPs are, and the regulatory hurdles to consider.

Click here to read the white paper.

We hope you find this article useful and would love to hear feedback about its content and related value to your business. Feel free to email me at jmetzger@nvca.org.

Over the coming months, keep a look out as we add more content to the NVCA website relating to fundraising, VC firm management and LP relations.

 

07

Feb

2013

Jim Healy Presents at FDA Hearing on Special Medical Use Pathway PDF Print E-mail

Kelly Sloane

Written by Kelly Slone   
Share

On February 4, FDA held a public hearing on a new proposal that would create an alternative approval pathway for certain drugs intended to address unmet medical need, also referred to as a Special Medical Use (SMU) designation.  Jim Healy, Managing General Partner, Sofinnova Ventures, presented NVCA’s perspective on the proposed new pathway before the FDA panel.

The SMU pathway was one of the recommendations that came out of the President’s Council of Advisors on Science and Technology (PCAST) report released last September entitled, “Report to the President on Propelling Innovation in Drug Discovery, Development, and Evaluation,” as a way to improve drug evaluation.

Under the proposed SMU pathway, the drug’s safety and effectiveness would be studied in a smaller subpopulation of patients with more serious manifestations of a condition and would likely involve smaller and more rapid clinical trials.  NVCA believes this new pathway could improve research and discovery in novel therapeutic areas, reduce the risk to patients and companies in the development of new treatments and encourage renewed funding of disease areas that are currently viewed as too risky or costly.

NVCA appreciates FDA’s continued efforts to explore thoughtful ways to increase patient access to innovative treatments.  We look forward to participating in an open dialogue with all stakeholders in working out the details of the SMU pathway.  There is tremendous promise here to promote innovation and improve discovery, development and regulatory review of new innovative treatments for important unmet medical needs.

Last Updated on Thursday, 07 February 2013 10:43
 

06

Feb

2013

VentureScape Presents...The World's Largest Office Hours PDF Print E-mail

Emily Mendell

Written by Emily Mendell   
Share

Today – with the premiere of our latest video -  NVCA officially announced the World’s Largest Office Hours which we will be hosting at VentureScape on May 14th from 3:00 – 5:30 p.m.  Check out the energy force that is building in San Francisco:

Click here to watch!

Office_Hours

A special thanks to the team at Scale Venture Partners including Kate Mitchell, Sharon Wienbar, Rory O’Driscoll, Rob Theis and Jaime Lovejoy who let us turn a giant leaf blower on them again and again and never complained once (well… maybe Rory had something to say.)  This video also stars Venky Ganesan of Globespan Capital Partners who is chairing the Office Hours event on behalf of our Board.  Rounding out the actors are the amazing team from Greenstart (Rachel Barge, Kacey Klonsky and Mandel Lum) and our own PR Counsel extraordinaire, Matthew Stotts from Tenor Communications.  I think we owe him a new shirt. The mustard was flying!  This video, like Deep Dives, was shot by the outstading team of Tom and Melissa Dowler at Long Haul Films.

And if you think the energy portrayed in the video is a stretch – we can tell you for certain that it is not.  We already have close to 50 of the best venture capital firms in the country signed up to meet with and mentor founders at Office Hours.  And the applications from entrepreneurs are pouring in.  You can read all about the firms, the process,  and how to apply at the VentureScape Office Hours site here.

We can't wait to see hundreds of you on May 14th!   Come into the light…..

 

 

 

04

Feb

2013

Corporate VC is Here to Stay PDF Print E-mail

John Taylor

Written by John Taylor   
Share
While statistically, 2012 wasn't a very dramatic investment year for U.S. venture capital (with a slight decline overall from 2011, but higher levels than 2010), corporate venture capital (CVC) continued to quietly gain strength. In 2012, CVC reached a 4-year high in participation (percent of deals with at least one corporate VC) of 15.2%, rising more than a percentage point from 14.1% in 2011. And dollar share also rose to 8.2% of total VC dollars in 2012, up from 7.5% last year.

Historically, it has been during difficult economic times that corporate venture programs have waned. So, it is significant that the CVC investment numbers have held steady as we have moved through the recession. This stability, coupled with more and more corporates joining the NVCA each year (it is our fastest growing new member segment), suggests that the sector is poised to become an even more important part of the VC landscape in the next five years.

Compared with total VC, corporate VCs are playing their largest roles in industrial/energy deals (21% of all deals have CVC in them), biotechnology (20%), computers (19%) and networking/equipment (18%). And within the CVC investment pool itself most dollars are being directed to companies operating in software (27% of all 2012 CVC dollars); biotechnology (21%) industrial/energy and IT Services (11% each).

Among the four stage categories (seed, early, expansion, and late), corporate groups far and away were most active in expansion stage deals measured by both total dollars invested (almost 10 % of all expansion stage dollars), deals completed (18% of all expansion deals) and 42% of all CVC investment.

For more information on corporate venture capital investment, check out our 2012 YE data here.

 

29

Jan

2013

Final Ruling on SBIR Grants = Victory for VC-Backed Companies PDF Print E-mail

Kelly Sloane

Written by Kelly Slone   
Share
After years of advocating for clarification on rules governing Small Business Innovative Research (SBIR) Grants so that venture-backed companies could qualify, we, at long last, have closure on this issue - and it is good news for our companies who seek government grants for critical, early stage basic research.

On December 28, the SBA issued a final rule amending its regulations governing size and eligibility for the SBIR and Small Business Technology Transfer (STTR) programs in accordance with the SBIR/STTR Reauthorization Act that passed Congress in 2011. Overall, the final rule, which is effective as of January 28, 2013, achieves a reasonable bright-line test for majority vc-backed small companies, and should ensure their ability to once again participate in the program. However, NVCA will be requesting that SBA provide greater clarity with certain provisions including the changes to the affiliation rules.

The Final Rule makes positive changes to the SBIR program's ownership and affiliation rules and allows an SBIR applicant to be more than 50 percent owned by multiple Investment Funds, as long as no single Investment Fund owns more than 50 percent of the applicant. A summary analysis from NVCA's counsel Mary Kuusisto of Proskauer can be viewed here.

We look forward to the positive impact this rule will have for our companies going forward.

 
<< Start < Prev 11 12 13 14 15 16 17 18 19 20 Next > End >>

Page 11 of 38